REG - Futura Medical PLC - Appointment of Roy Davis as Non-Executive Director

Futura MedicalAnnouncement

09/01/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240109:nRSI9948Ya&default-theme=true

RNS Number : 9948Y  Futura Medical PLC  09 January 2024

 

09 January 2024

 Futura Medical plc

Appointment of Roy Davis as Non-Executive Director

 

Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), the pharmaceutical
company developing innovative sexual health products, today announces the
appointment of Roy Davis as a Non-Executive Director with immediate effect.

 

Roy brings a wealth of commercial experience in medical devices companies and
has a proven track record of successfully scaling companies and delivering
substantial value for shareholders. He has held leadership positions at a
number of publicly quoted med tech companies, including CEO of Optos plc, a
leading retinal imaging device manufacturer, from 2008 to 2016 until its sale
to Nikon for £259m in February 2015. From 2007 to 2008, Roy was CEO of Gyrus
Group plc, a leader in minimally invasive surgery and visualisation, until its
acquisition by Olympus Corporation in 2008 for $1.9 billion.

 

He is currently Non-Executive Chair at LungLife AI plc, Foster and Freeman
(the trading name of the Galton group of companies) and Rair Health Ltd and
was until recently, Non-Executive Chair at Medica Group plc until its
acquisition by IK Partners for £269 million earlier this year.  On 7
December it was announced that Roy will become a Non-Executive Director and
Chair Designate of Inspiration Healthcare Group plc with effect from 25
January 2024.

 

Jeff Needham, Chairman of Futura Medical said: "Roy brings with him
significant commercial expertise and a proven track record of creating
substantial shareholder value. His appointment will add to the depth and
breadth of experience of the Futura Board as we continue to monetise our key
asset, Eroxon, move towards profitability, and deliver on our strategy."

Roy Davis, said: "I am delighted to be joining the Board of Futura. The
Company is providing novel solutions in the sexual health sector and has
exciting opportunities ahead of it. I look forward to working with the Board
and Executive Team to help execute the strategy and deliver shareholder
value."

In accordance with Schedule 2 (g) of the AIM Rules for Companies, Gordon Roy
Davis (aged 67 years) holds/has held the following directorships/partnerships
in the last five years:

 

 Current directorships/partnerships  Previous directorships/partnerships (last five years)
 LungLifeAI, Inc                     Medica Group plc

 Rair Health Limited                 Edinburgh Molecular Imaging Limited

 Galton Bidco Limited

 Galton Midco Limited

 Galton Topco Limited

 Galton Tradeco Limited

 

In addition to the above, Roy Davis was a director of C-Quential Limited until
his resignation on 28 February 2001. The company entered into a creditors
voluntary liquidation on 11 February 2002 and was subsequently dissolved on 18
August 2007.

 

Roy Davis currently holds no ordinary shares in the Company.

 

There are no further disclosures to be made under Schedule 2(g) of the AIM
Rules for Companies.

 

ENDS

 

 

For further information please contact:

 

Futura Medical plc

James Barder, Chief Executive Officer

Angela Hildreth, Finance Director and COO

Email: investor.relations@futuramedical.com
(mailto:Investor.relations@futuramedical.com)

Tel: +44 (0) 1483 685 670

www.futuramedical.com (http://www.futuramedical.com/)

 

Nominated Adviser and Sole Broker:

 

Liberum

Phil Walker/ Ben Cryer/Nikhil Varghese

Tel: +44 (0) 20 3100 2000

 

For media enquiries please contact:

Optimum Strategic Communications

Nick Bastin / Jonathan Edwards / Elena Bates

Email: futuramedical@optimumcomms.com

Tel: +44 (0) 203 882 9621

 

 

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a
portfolio of innovative sexual health products based on its proprietary,
transdermal DermaSys® technology. Each DermaSys® formulation is separately
patented and specifically tailored for the selected indication and
application, as well as being optimised for clinical efficacy, safety,
administration and patient convenience. The products are developed for the
prescription and consumer healthcare markets as appropriate. Development and
commercialisation strategies are designed to maximise product differentiation
and value creation whilst minimising risk.

MED3000 is Futura's topical gel formulation that is a novel treatment for
erectile dysfunction (ED) through a unique evaporative mode of action and is
sold in Europe and the UK under the brand name Eroxon®. Futura has conducted
two Phase 3 studies using MED3000 in ED; the FM57 study which enabled Futura
to be granted a CE Mark in 2021 and FM71 which enabled Futura to be granted US
marketing authorisation. Both studies demonstrated that MED3000 presents an
effective clinically proven treatment for ED with a rapid speed of onset and a
favourable benefit versus risk profile ideally suited for an 'Over the
Counter' classification.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market
of the London Stock Exchange. www.futuramedical.com
(http://www.futuramedical.com/)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAUPUBPGUPCGAR